A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

Human Psychopharmacology
Olivier VittonSrinivas G Rao

Abstract

Fibromyalgia syndrome is a systemic disorder of widespread pain which is thought to result from abnormal pain processing within the central nervous system. There are no currently approved treatments for this indication. Antidepressants appear, however, to be effective, especially those with an action on noradrenergic neurotransmission. The objective of the present study was to test the efficacy of the dual action noradrenaline and serotonin reuptake inhibitor antidepressant, milnacipran, in the treatment of fibromyalgia. The 125 patients, who were enrolled in a double-blind, placebo-controlled, flexible dose escalation trial, were randomized to receive placebo or milnacipran for 4 weeks of dose escalation (up to 200 mg/day), followed by 8 weeks at a constant dose. The study evaluated the efficacy and safety of milnacipran for the treatment of pain and associated symptoms such as fatigue, depressed mood and sleep. 75% of milnacipran-treated patients reported overall improvement, compared with 38% in the placebo group (p < 0.01). Furthermore, 37% of twice daily milnacipran-treated patients reported at least 50% reduction in pain intensity, compared with 14% of placebo-treated patients (p < 0.05). 84% of all milnacipran patients e...Continue Reading

References

May 1, 1996·Rheumatic Diseases Clinics of North America·J I Hudson, H G Pope
Sep 1, 1996·International Clinical Psychopharmacology·M BrileyC Moret
Sep 18, 1999·Lancet·S WesselyM Sharpe
Dec 28, 1999·Annals of Internal Medicine·L J Leventhal
Feb 29, 2000·Journal of Sex & Marital Therapy·C A McGahueyR Manber
Apr 6, 2000·Psychosomatics·L M ArnoldJ A Welge
Aug 19, 2000·Annals of Medicine·D Fishbain
Oct 13, 2000·Journal of General Internal Medicine·P G O'MalleyJ L Jackson
Jun 14, 2001·Current Pain and Headache Reports·K P White, M Harth
May 23, 2002·BMJ : British Medical Journal·Arthur A StoneMichael R Hufford
Sep 3, 2002·Journal of Affective Disorders·A P Van AmerongenA Tournoux
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Feb 11, 2004·Current Opinion in Rheumatology·Roland Staud

❮ Previous
Next ❯

Citations

Sep 9, 2011·Zeitschrift für Rheumatologie·M Späth
May 7, 2008·Der Schmerz·C SommerD O Nutzinger
Jul 5, 2012·Der Schmerz·C SommerUNKNOWN Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
Nov 12, 2005·Current Pain and Headache Reports·Dina Dadabhoy, Daniel J Clauw
Oct 15, 2008·Nature Clinical Practice. Neurology·Eric Serra
Jul 31, 2012·International Journal of Dentistry·Yoshihiro AbikoAkira Toyofuku
Aug 1, 2010·Therapeutic Advances in Musculoskeletal Disease·Chad S Boomershine
Dec 3, 2013·Arthritis Research & Therapy·Ann VincentLeorey N Saligan
Jan 5, 2011·Journal of Pain Research·Michelle J OrmsethChad S Boomershine
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Nurcan UçeylerClaudia Sommer
Apr 2, 2009·Neuropsychiatric Disease and Treatment·Kim Lawson
Sep 1, 2006·Neuropsychiatric Disease and Treatment·Akira Toyofuku, Toshihiro Kikuta
Nov 26, 2009·Patient Preference and Adherence·Eric NantzVladimir Skljarevski
Feb 25, 2006·Primary Care Companion to the Journal of Clinical Psychiatry
May 7, 2008·Primary Care Companion to the Journal of Clinical Psychiatry
Nov 1, 2005·Women's Health·Andrew J Holman
Aug 20, 2014·Pain and Therapy·Akiko Okifuji, Bradford D Hare
Mar 20, 2013·Expert Opinion on Pharmacotherapy·Cheryl D BernsteinDawn A Marcus
May 22, 2010·Expert Opinion on Emerging Drugs·Jacob N Ablin, Dan Buskila
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Roland Staud
Jan 1, 2006·International Journal of Psychiatry in Clinical Practice·Pedro L Delgado
Mar 7, 2008·Expert Opinion on Emerging Drugs·Jacob N Ablin, Dan Buskila
Aug 4, 2011·Current Medical Research and Opinion·Peter SunPeter Watson
Jul 9, 2008·Current Medical Research and Opinion·Chi-Un PaeBoudewijn Van Houdenhove
Jun 8, 2013·Maturitas·Jacob N Ablin, Dan Buskila
Oct 15, 2011·European Journal of Pharmacology·Ronan DepoortèreAdrian Newman-Tancredi
Aug 27, 2011·Seminars in Arthritis and Rheumatism·Ernest ChoyHelen A Dakin
Jun 2, 2011·Disease-a-month : DM·Howard S Smith, Robert L Barkin
Sep 1, 2010·Asian Journal of Psychiatry·Kaustav ChakrabortySuresh Kumar
Apr 27, 2010·The Journal of Pain : Official Journal of the American Pain Society·Winfried HäuserClaudia Sommer
Aug 4, 2009·Rheumatic Diseases Clinics of North America·I Jon Russell, Alice A Larson
Aug 1, 2009·Reumatología clinica·Antonio Collado, Arantxa Conesa
Jan 21, 2009·Seminars in Arthritis and Rheumatism·Philip J MeaseAmy S Chappell
Mar 1, 2006·Reumatología clinica·A Alonso-RuizL Carmona-Ortells
May 27, 2008·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Chi-Un PaePrakash S Masand
Oct 16, 2007·The Journal of Pain : Official Journal of the American Pain Society·Dennis C TurkNathan J Rudin
Oct 1, 2009·Arthritis and Rheumatism·Richard E HarrisDaniel J Clauw
Sep 2, 2008·Arthritis and Rheumatism·Nurcan UçeylerClaudia Sommer
Mar 28, 2008·Pain Practice : the Official Journal of World Institute of Pain·Serge PerrotRobert M Bennett
Apr 1, 2008·Pain Practice : the Official Journal of World Institute of Pain·Stefano CoaccioliAdolfo Puxeddu

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.